Fredun Pharmaceuticals Ltd

Net profit of Fredun Pharmaceuticals rose 96.62% to Rs 10.48 crore in the quarter ended December 2025 as against Rs 5.33 crore during the previous quarter ended December 2024. Sales rose 57.04% to Rs 159.93 crore in the quarter ended December 2025 as against Rs 101.84 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales159.93101.84 57 OPM %16.4612.98 - PBDT15.788.22 92 PBT14.007.13 96 NP10.485.33 97 Powered by Capital Market - Live

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 16 February 2026.Powered by Capital Market - Live

The board of Fredun Pharmaceuticals at its meeting held on 29 December 2025 has approved allotment of 6,44,360 equity shares at an issue price of Rs 1250 (including a premium of Rs 1240) on preferential basis for a cash consideration of Rs 80.54 crore payable in cash; The board also approved allotment of 5,51,600 convertible warrants at an exercise price of Rs 1250 per warrant aggregating to Rs 68.95 crore, upon receipt of Rs 312.50 (being 25% of the issue price of warrant) amounting to Rs 17.23 crore as subscription price. Powered by Capital Market - Live

Net profit of Fredun Pharmaceuticals rose 127.87% to Rs 9.73 crore in the quarter ended September 2025 as against Rs 4.27 crore during the previous quarter ended September 2024. Sales rose 34.33% to Rs 143.59 crore in the quarter ended September 2025 as against Rs 106.89 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales143.59106.89 34 OPM %15.5513.04 - PBDT14.608.63 69 PBT13.007.57 72 NP9.734.27 128 Powered by Capital Market - Live

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2025.Powered by Capital Market - Live

The product, launched under Fredun's Freossi brand, is free from root vegetables, meat, and animal-derived ingredients, in line with Jain dietary principles. It is designed to support pet immunity, digestion, bone health, and energy. Snacky Jain will be initially available in six cities through veterinary clinics, online platforms, and retail partners, with expansion planned for Ahmedabad, Pune, Bengaluru, and Delhi. The product is manufactured at the company's WHO-GMP-certified Palghar facility. Fredun said the launch strengthens its position in India's pet healthcare market, estimated at Rs 10,000 crore and growing at over 22% annually. Fredun Pharmaceuticals, a healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. On a standalone basis, Fredun Pharmaceuticals' net profit rose 63.92% to Rs 6.77 crore while net sales rose 53.99% to Rs 119.40 crore in Q1 June 2025 over Q1 June 2024. Powered by Capital Market - Live

Fredun Pharmaceuticals announced the launch of 'Snacky Jain' ' a true first of its kind, and India's first Jain functional food product specifically for pets. Snacky Jain, developed under the flagship Freossi brand, is a truly pioneering step in pet nutrition, establishing a new standard for ethical, inclusive feeding. The product is the first of its kind to be thoughtfully crafted to align with Jain dietary principles, being completely free from root vegetables, meat, and all animal-derived ingredients. Critically, it still delivers essential nutrients to support superior immunity, digestion, bone health, and energy in pets. This innovation reinforces Fredun's commitment to creating a 360' pet wellness ecosystem encompassing nutrition, grooming, diagnostics, and preventive care. Developed through in-house R&D, Snacky Jain combines natural, plant-based ingredients with functional health benefits, ensuring both taste and wellness for companion animals. Snacky Jain will be initially introduced across six cities, through veterinary clinics, online marketplaces, and Fredun's dedicated retail partners, with phased expansion planned for key pet care markets including Ahmedabad, Pune, Bengaluru, and Delhi. The product is manufactured at Fredun's WHO-GMP-certified Palghar facility, ensuring international standards of quality and safety. Powered by Capital Market - Live

Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 October 2025.Powered by Capital Market - Live

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 25 September 2025.Powered by Capital Market - Live